--- canonical_name: MA-5 alternate_names: Mitochonic Acid 5, Mitochonic Acid-5, 4-(2,4-difluorophenyl)-2-(1H-indol-3-yl)-4-oxobutanoic acid canonical_topic: MA-5 for Health & Longevity short_topic_lc: ma_5 creation_date: 2026-0905-0957 creator_ai_fullname: Opus 5 ep_keywords: Mitochondrial Enhancers, Mitochondria-Targeted Compounds, Indole Derivatives --- # MA-5 for Health & Longevity
Evidence Review created on 09/05/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 5 **Also known as:** Mitochonic Acid 5, Mitochonic Acid-5, 4-(2,4-difluorophenyl)-2-(1H-indol-3-yl)-4-oxobutanoic acid ## Motivation MA-5 (mitochonic acid 5) is a small synthetic molecule built from the backbone of a common plant growth hormone. It was designed to make failing mitochondria produce more energy, and the proposed explanation is that it changes the shape of the folded inner membrane where energy is made rather than pushing the usual chemical reactions harder. Interest in it outside rare-disease medicine comes from a simple observation: the same loss of mitochondrial energy output that defines inherited energy disorders also accompanies ordinary aging. The compound emerged from a Japanese screen of plant-hormone analogues chosen for their ability to raise energy levels in cultured cells. Work since then has moved it through cells taken from patients with inherited energy disorders, through worms, and through mice with kidney, hearing and movement problems. It has now reached people: an early safety study in healthy volunteers has been completed, and a placebo-controlled hospital study in patients is under way in Japan. This review examines what MA-5 is, how it is proposed to work, what the laboratory and animal evidence establishes and what it does not, what is known and unknown about its safety, and how far it sits from ordinary use. **[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)** ## Recommended Reading The items below give a high-level orientation to MA-5, its proposed mechanism, its aging-relevant effects, and the first independent challenge to its target story. * [Mitochonic acid 5 attenuates age-related neuromuscular dysfunction associated with mitochondrial Ca2+ overload in *Caenorhabditis elegans*](https://pubmed.ncbi.nlm.nih.gov/37528117/) - Wu et al., 2023 The single most longevity-relevant MA-5 paper: it tests the compound against normal aging rather than against a disease mutation, and reports preserved movement and neuron counts. * [Mitochonic acid 5 mitigates age-related hearing loss progression by targeting defective 2-methylthiolation in mitochondrial transfer RNAs](https://pubmed.ncbi.nlm.nih.gov/40260078/) - Kouga et al., 2025 The strongest mammalian aging result, and the study that motivated the current human trial. Useful for seeing which outcomes were measured directly and which were inferred. * [Therapeutic potential of mitochonic acid (MA-5) in modulating mitochondrial function and inflammatory responses: A focus on carnitine/acylcarnitine carrier (SLC25A20) transport activity](https://pubmed.ncbi.nlm.nih.gov/42217682/) - Giangregorio et al., 2026 The first fully independent characterization of MA-5, and the only one reporting an off-target effect on SLC25A20 (the mitochondrial fatty-acid carrier). Essential counterweight to the developer-generated literature. * [Mitochonic acid 5 rescues cardiomyocytes from doxorubicin-induced toxicity via repressing the TNF-α/NF-κB/NLRP3-mediated pyroptosis](https://pubmed.ncbi.nlm.nih.gov/37549513/) - Zha et al., 2023 Shows how a second research community adopted MA-5 as an anti-inflammatory tool, working through the inflammatory signaling proteins named in its title rather than through cristae shape. * [Effects of an indole chemical, mitochonic acid 5, in a mouse model of mitochondrial disease onset](https://pubmed.ncbi.nlm.nih.gov/42270754/) - Ogasawara et al., 2026 The most rigorous animal study to date: blinded, randomized, placebo-controlled, and unusually candid about which endpoints moved and which did not. Section note: none of the six priority experts and publications listed in the AI4L guideline has covered MA-5, because the compound has never been marketed as a supplement and has had no English-language consumer coverage; two independent searches per platform confirmed the absence. Only five high-quality sources are listed and the list has not been padded, because the total published literature on MA-5 is roughly thirty papers. Conflict of interest, stated here at first citation: the compound's founding literature and its clinical development — including the Wu and Ogasawara papers above — originate from or include the Tohoku University group of Takaaki Abe, who invented MA-5 and leads its path to approval, and the program is funded by the Japan Agency for Medical Research and Development, a national body with a stake in that outcome. The Kouga, Giangregorio and Zha papers come from unaffiliated groups. ## Grokipedia No Grokipedia article exists for MA-5. ## Examine No Examine article exists for MA-5. MA-5 is an unapproved investigational drug on a prescription-medicine development path rather than a dietary supplement ingredient, and Examine.com does not typically cover prescription or investigational medications. ## ConsumerLab No ConsumerLab article exists for MA-5. ConsumerLab tests retail dietary supplements; MA-5 is an unapproved investigational prescription-track drug sold only as a research chemical, and ConsumerLab does not typically cover prescription or investigational medications. ## Systematic Reviews No systematic reviews or meta-analyses for MA-5 were found on PubMed as of September 5, 2026. Both sides of the trade-off are therefore unrepresented in this section: there is no systematic review or meta-analysis covering the claimed effect (restoration of mitochondrial energy output) and none covering the principal risk (off-target inhibition of mitochondrial fatty-acid transport). ## Mechanism of Action MA-5 is a synthetic derivative of indole-3-acetic acid, the principal growth hormone of plants. It was picked from a chemical library because it raised ATP (adenosine triphosphate, the molecule cells spend as energy) in cultured human liver cells; fluorescent tracing showed it concentrates inside mitochondria rather than at the cell surface ([Suzuki et al., 2015](https://pubmed.ncbi.nlm.nih.gov/26118651/)). Its proposed target is mitofilin, also called Mic60 — the anchor protein of the MICOS complex (the mitochondrial contact site and cristae organizing system, the scaffold that holds the folded inner membrane in shape). Binding mitofilin is thought to stabilize that folding, promoting oligomerization (side-by-side stacking) of ATP synthase, the enzyme that makes ATP, and assembly of respiratory supercomplexes. The reported consequence is more ATP with fewer reactive oxygen species (ROS, the damaging by-products of oxygen metabolism) and less mitochondrial fragmentation ([Matsuhashi et al., 2017](https://pubmed.ncbi.nlm.nih.gov/28579242/)). Crucially, complexes I–IV of the electron transport chain (the membrane relay that normally drives energy production) are unchanged, which is why the effect survives chemical blockade of oxidative phosphorylation (the oxygen-driven route to ATP). Pharmacologically, MA-5 is a small lipophilic carboxylic acid, orally active in rodents, distributing to kidney, heart and skeletal muscle. Its human half-life and metabolic route are not published. Selectivity is imperfect: an independent group reports non-competitive, reversible inhibition of the carnitine/acylcarnitine carrier SLC25A20 (the shuttle that moves fatty acids into mitochondria), a competing explanation under which part of its profile reflects altered fuel flux, not cristae remodeling ([Giangregorio et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42217682/)). ## Historical Context & Evolution MA-5 was not repurposed; it was made to order. Its parent molecule, indole-3-acetic acid, is the auxin that regulates plant growth, and a Tohoku University group screened auxin analogues for one property: raising ATP in cells. The winning compound was named mitochonic acid 5 after it improved survival of skin cells from patients with Leigh syndrome (a severe inherited brain energy disorder) and three other inherited mitochondrial diseases ([Suzuki et al., 2015](https://pubmed.ncbi.nlm.nih.gov/26118651/)). Its original intended use was therefore narrow: rare inherited energy disorders, and the kidney and heart injury that accompanies them ([Suzuki et al., 2016](https://pubmed.ncbi.nlm.nih.gov/26609120/)). It entered the health-optimization conversation because the deficits it corrects in disease models — cristae collapse, falling ATP, rising oxidative by-products — are the same changes that accompany normal aging. Work in *Caenorhabditis elegans* on age-related motor decline ([Wu et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37528117/)) and in mice on age-related hearing loss ([Kouga et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40260078/)) made that leap explicit. Scientific opinion has not settled. The compound was first framed as an alternative to antioxidant therapy; the mechanism was refined from "ATP enhancer" to a mitofilin/cristae story; then an independent laboratory added an off-target transporter effect the original account does not predict ([Giangregorio et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42217682/)). Nothing has been retracted or shown irreproducible, and the earlier findings still stand on their own data — but the single-target picture is no longer the only reading, and blinded replication found some endpoints moved while others did not ([Ogasawara et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42270754/)). ## Expected Benefits ### High 🟩 🟩 🟩 No benefit reaches High: there is no replicated human clinical endpoint or validated clinical surrogate for MA-5, because no trial result in people has been published at all. ### Medium 🟩 🟩 No benefit reaches Medium: there is no single human trial and no observational human dataset for MA-5 — the closest human material is patient-derived cells treated in a dish, which is in-vitro evidence. ### Low 🟩 ### Speculative 🟨 #### Increased Cellular ATP Output MA-5 raised ATP in liver and fibroblast cultures even when oxidative phosphorylation was blocked ([Suzuki et al., 2015](https://pubmed.ncbi.nlm.nih.gov/26118651/)). No human tissue measurement exists; the basis is in-vitro only. #### Reduced Mitochondrial Oxidative Stress Reactive oxygen species fell in treated cells while ATP rose, attributed to cristae stabilization rather than radical scavenging ([Matsuhashi et al., 2017](https://pubmed.ncbi.nlm.nih.gov/28579242/)). Evidence is in-vitro and animal only, on unvalidated biomarkers. #### Rescue of Patient-Derived Mitochondrial Disease Cells Fibroblasts from 24 of 25 mitochondrial-disease patients survived stress better with MA-5 ([Matsuhashi et al., 2017](https://pubmed.ncbi.nlm.nih.gov/28579242/)). Survival in a dish is not a clinical outcome; no human endpoint exists. #### Extended Survival in Mitochondrial Disease Models In mice carrying deleted mitochondrial DNA, MA-5 appeared to prolong survival, though the study could not test this statistically ([Suzuki et al., 2016](https://pubmed.ncbi.nlm.nih.gov/26609120/)). No lifespan measurement exists in normal animals or in people. #### Preserved Kidney Structure and Function In blinded, placebo-controlled mice with deleted mitochondrial DNA, MA-5 normalized creatinine and histology and reduced kidney weight ([Ogasawara et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42270754/)). The finding is rodent-only; no human renal data exist. #### Slowed Age-Related Hearing Loss In mice with early hearing loss, MA-5 improved hearing thresholds and preserved cochlear hair cells ([Kouga et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40260078/)). This mammalian result drives the current human trial, but remains animal-only. #### Preserved Motor Function and Dopaminergic Neurons in Aging In *Caenorhabditis elegans*, MA-5 slowed age-related loss of movement, muscle mitochondria and dopamine neurons ([Wu et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37528117/)). The only test against normal aging rather than disease, and invertebrate. #### Reduced Neuroinflammation MA-5 reduced inflammatory signaling and cell death in mouse brain immune cells by promoting clearance of damaged mitochondria ([Tan et al., 2021](https://pubmed.ncbi.nlm.nih.gov/33510088/)). Evidence is cultured-cell and rodent only; no human measurement exists. #### Cardiac Protection Under Toxic and Genetic Stress ⚠️ Conflicted MA-5 protected heart cells from doxorubicin ([Zha et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37549513/)); blinded mice showed no cardiac histological gain, only partial recovery of respiratory-chain proteins ([Ogasawara et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42270754/)). Net reading: cardiac protection is unreliable. ## Benefit-Modifying Factors * **Mitochondrial DNA mutation load:** Benefit in mice appeared only where deleted mitochondrial DNA exceeded roughly 60–80% of the total ([Ogasawara et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42270754/)). People with a low mutation load, or with normal mitochondria, may have little dysfunction left for MA-5 to correct. * **Baseline GDF-15 and lactate:** GDF-15 (growth differentiation factor 15, a blood protein that rises when mitochondria are stressed) and blood lactate track the deficit MA-5 targets. Animals with normal values showed the smallest changes ([Ogasawara et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42270754/)), suggesting a floor effect. * **Nuclear versus mitochondrial genetic cause:** Response in patient fibroblasts spanned many mutations ([Matsuhashi et al., 2017](https://pubmed.ncbi.nlm.nih.gov/28579242/)), but MICOS-complex and cristae-shaping variants (for example affecting mitofilin or OPA1, a fusion protein) would blunt a mechanism working through cristae geometry. * **Sex-based differences:** Unknown. Published mammalian work used male animals, the invertebrate work used hermaphrodites, and no study reports a sex-stratified analysis, so no sex difference in benefit has been examined. * **Pre-existing kidney and cochlear disease:** The largest effects appeared where the target organ was already failing — enlarged, scarred kidneys and degenerating cochleae ([Ogasawara et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42270754/)). Healthy organs in the same animals showed no measurable gain. * **Age at exposure:** In worms, MA-5 acted on the rate of decline rather than reversing it ([Wu et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37528117/)). Whether starting later in life, at the older end of the target range, retains any effect is untested. ## Potential Risks & Side Effects ### High 🟥 🟥 🟥 No risk reaches High: no documented adverse event, clinical endpoint or validated clinical surrogate has been reported for MA-5 in more than one human trial, because no human trial result has been published. ### Medium 🟥 🟥 No risk reaches Medium: there is no single published human trial and no observational human safety dataset for MA-5 — the completed Phase I study exists only as an unpublished summary statement. ### Low 🟥 ### Speculative 🟨 #### Inhibition of the Mitochondrial Carnitine Shuttle MA-5 reversibly inhibited SLC25A20, which carries fatty acids into mitochondria, at 58–73 µM in vitro ([Giangregorio et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42217682/)). Whether human tissue reaches those concentrations is unknown; no in-vivo data exist. #### Uncharacterized Adverse-Event Profile in Humans The only human exposure is a Phase I study reported through press releases as showing almost no side effects, without published adverse-event data ([Science Japan report](https://sj.jst.go.jp/news/202601/n0119-01k.html)). The basis is an unverifiable claim. #### Support of Malignant Cell Survival MA-5 was discovered by raising ATP in a liver cancer line and promotes cell survival under stress ([Suzuki et al., 2015](https://pubmed.ncbi.nlm.nih.gov/26118651/)). No tumor-growth study exists; the concern is mechanistic only. #### Impurities and Misidentification in Research-Chemical Supply MA-5 exists commercially only as a research chemical sold explicitly not for human use. No pharmacopoeial monograph, batch release standard or contaminant limit applies. The basis is regulatory, with no measured exposure data. #### Solvent Load From Non-Pharmaceutical Formulations MA-5 is poorly water-soluble; published animal work dissolves it in dimethyl sulfoxide with corn oil ([Ogasawara et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42270754/)). Self-prepared solutions would deliver that solvent at unstudied doses. ## Risk-Modifying Factors * **Fatty-acid oxidation genotype:** Carriers of variants in *SLC25A20*, *CPT2* or other fatty-acid transport genes already have reduced capacity to move fats into mitochondria, and would be expected to tolerate a carnitine-shuttle inhibitor least well. * **Baseline carnitine and acylcarnitine profile:** Low free carnitine, or a raised acylcarnitine-to-free-carnitine ratio, marks a shuttle already under strain. Such a baseline converts a theoretical off-target effect into a plausible clinical one. * **Sex-based differences:** Unknown and unexamined. Published rodent work used male animals only, and no published work stratifies MA-5 tolerability, exposure or clearance by sex in any species. * **Pre-existing hepatic, renal or oncological disease:** Impaired liver or kidney clearance would raise exposure of a compound whose human elimination route is unpublished, and an active or recent malignancy intersects with the cell-survival concern. * **Age-related fasting tolerance:** Older adults, including those at the upper end of the target range, depend more on fatty-acid oxidation during fasting and overnight. Any shuttle inhibition would surface first as fasting fatigue in that group. ## Key Interactions & Contraindications No interaction has been documented in humans. Every entry below is mechanism-based, derived from MA-5's known targets, and should be read as a hypothesis rather than an observation. * **Carnitine-dependent therapy (levocarnitine, acetyl-L-carnitine):** Caution. MA-5 inhibits the carrier these agents feed, so a supplement taken for fatty-acid transport may be neutralized. Mitigation: separate dosing by several hours and measure free and total carnitine. * **Complex I inhibitors (metformin, phenformin):** Caution. Both reduce mitochondrial respiration while MA-5 is given to restore it, so effects may oppose. Consequence: unpredictable lactate response. Mitigation: measure lactate before and four weeks after starting. * **Anthracycline chemotherapy (doxorubicin, epirubicin):** Caution. MA-5 opposes anthracycline cardiotoxicity in cells, but it also raises tumor-cell ATP. Consequence: possible reduced antitumor effect. Mitigation: absolute avoidance during active cancer treatment. * **CYP3A4 substrates and inhibitors (ketoconazole, ritonavir, grapefruit juice):** Caution on principle only. MA-5's metabolizing enzymes (CYP enzymes are the liver's main drug-clearing system) are unpublished. Consequence: unbounded over- or under-exposure to either agent, meaning unpredictable toxicity or loss of effect. * **Over-the-counter medications (high-dose ibuprofen, naproxen, paracetamol):** Caution. All three stress mitochondria at high dose, opposing MA-5's intent and loading the same liver clearance. Consequence: additive mitochondrial strain. Mitigation: keep to labeled doses. * **Supplements with additive mitochondrial effects (coenzyme Q10, ubiquinol, nicotinamide riboside, alpha-lipoic acid, creatine):** Monitor. Additive by design; all raise energy availability. Consequence: no known harm, but efficacy attribution becomes impossible. Mitigation: introduce one agent at a time. * **High-dose antioxidants (vitamin C above 2 g daily, vitamin E above 400 IU daily):** Caution. MA-5's reported benefit runs partly through controlled reactive oxygen species signaling, which megadose antioxidants blunt. Consequence: possible loss of effect. Mitigation: keep intakes near dietary levels. * **Other interventions (ketogenic diets, prolonged fasting, endurance training):** Caution. All three shift fuel use toward fatty acids and therefore toward the carrier MA-5 inhibits. Consequence: exercise or fasting intolerance. Mitigation: avoid combining with a first exposure. **Populations who should avoid MA-5:** * Anyone unable to obtain material made to pharmaceutical standard, which currently means everyone outside the registered Japanese trial * Pregnancy and lactation — no reproductive toxicity data exist in any species * People under 18 outside a registered trial * Diagnosed fatty-acid oxidation disorders — carnitine-acylcarnitine translocase deficiency, carnitine palmitoyltransferase II deficiency, primary carnitine deficiency * Active malignancy, or malignancy in remission for under 5 years * Advanced liver disease — Child-Pugh Class B or C * Advanced kidney disease — estimated glomerular filtration rate below 30 mL/min/1.73 m² ## Risk Mitigation Strategies * **Deferral pending published human data:** The most effective mitigation for every risk listed above is waiting for the Phase II results, since no self-directed protocol can substitute for an adverse-event dataset that does not yet exist. * **Certificate of analysis before any exposure:** Requiring batch-specific identity by nuclear magnetic resonance and purity above 98% by high-performance liquid chromatography mitigates the impurity and misidentification risk inherent in research-chemical supply. * **Baseline and 4-week carnitine panel:** Measuring free carnitine, total carnitine and the acylcarnitine ratio before starting and at 4 weeks detects the carnitine-shuttle inhibition seen in reconstituted systems before it produces symptoms. * **Avoidance during fasting or prolonged endurance work:** Not combining MA-5 with states that depend on fatty-acid oxidation reduces the chance that shuttle inhibition manifests as hypoglycemia (low blood sugar) or exercise intolerance. * **Oncological screening and exclusion:** Age-appropriate cancer screening before starting, and exclusion during active or recently treated malignancy, addresses the theoretical risk that raising cell ATP supports malignant cell survival. * **Avoid self-prepared solvent vehicles:** Not reproducing laboratory dimethyl sulfoxide vehicles avoids delivering an unstudied solvent dose alongside the compound, which is a distinct exposure from MA-5 itself. * **Single-variable introduction:** Adding no other mitochondrial agent for at least 8 weeks keeps any adverse change attributable, which matters most where no adverse-event profile exists to compare against. ## Therapeutic Protocol * **No practitioner protocol exists:** MA-5 is not prescribed by any clinician anywhere. No integrative clinic, longevity practice or compounding pharmacy has published a protocol, and no dose used in humans has been disclosed in any peer-reviewed source. * **The only structured human protocol:** The investigator-initiated Phase II study administers oral MA-5 at low dose, high dose or placebo, double-blind, to patients with mitochondrial disease and hearing loss ([Tohoku University announcement](https://www.tohoku.ac.jp/en/news/university_news/worlds_first_mitochondrial_disease_treatment_commences_clinical_trial.html)). * **Competing approaches — conventional versus mitochondrial-targeted:** Conventional care for mitochondrial dysfunction remains supportive, with coenzyme Q10, riboflavin, creatine and taurine cocktails. Neither approach is presented here as the default; MA-5 is the newer and far less tested of the two. * **Who popularized the approach:** The mitofilin-targeting strategy was originated and is still driven by Takaaki Abe's group at Tohoku University; no independent clinic has adopted it. * **Rodent exposure for reference:** Blinded mouse work used 50 mg/kg body weight once daily by oral gavage in corn oil for 27 days ([Ogasawara et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42270754/)). This does not translate directly to a human dose. * **Invertebrate exposure for reference:** Worm work used 10 µM MA-5 in the culture medium throughout adult life ([Wu et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37528117/)). Culture concentrations have no defined human equivalent. * **Timing of day:** Untested. All published animal dosing was once daily without a stated time, so no morning or evening advantage has been established for a compound whose human half-life is unknown. * **Half-life:** Not published for humans. Once-daily rodent dosing produced sustained tissue effects, implying a half-life long enough for daily administration, but this is inference rather than measurement. * **Single versus split dosing:** Untested. Every published protocol in every species used a single daily administration; no study has compared divided doses against once-daily exposure. * **Genetic polymorphisms influencing dose:** None validated. Variants in fatty-acid transport genes such as *SLC25A20* and *CPT2* are mechanistically relevant to tolerance, and mitochondrial haplogroup may affect baseline deficit, but no pharmacogenetic data exist. * **Sex-based differences in response:** Unexamined. Published mammalian work used male mice; the human trial is not powered for sex-stratified analysis, so no dosing difference between men and women can be stated. * **Age-related considerations:** No dose adjustment can be specified. Older adults, including at the upper end of the target range, have reduced renal and hepatic clearance, and MA-5's elimination route is unpublished. * **Baseline biomarkers influencing response:** Animal response tracked baseline deficit — high lactate, high GDF-15, high mutation load ([Ogasawara et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42270754/)). Normal baseline values predicted little measurable change, so response is likely proportional to existing dysfunction. * **Pre-existing conditions influencing response:** Kidney disease driven by mitochondrial dysfunction showed the clearest animal response; heart tissue responded inconsistently ([Ogasawara et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42270754/)), and no response has been characterized in metabolically healthy tissue. ## Discontinuation & Cycling * **Lifelong versus short-term:** Undetermined. The compound is being developed as continuous therapy for a chronic genetic disease, but no study has examined whether effects persist, plateau or reverse after stopping. * **Withdrawal effects:** None reported. No animal or human study has included a washout arm, so the absence of documented withdrawal reflects absence of investigation rather than evidence of safety on stopping. * **Tapering protocol:** No tapering protocol exists or is mechanistically indicated. MA-5 has no receptor-mediated tolerance or dependence pathway identified, so abrupt cessation carries no known physiological rebound. * **Cycling for maintained efficacy:** Not studied. Published protocols dosed continuously — 27 days in mice, adult life in worms ([Ogasawara et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42270754/)) — and no comparison of intermittent against continuous exposure exists. * **Duration of observed effect:** In the longest blinded mammalian study, kidney benefits were measured after 27 days of daily dosing, with body weight diverging from placebo around day 18 ([Ogasawara et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42270754/)). Nothing is known beyond that horizon. ## Sourcing and Quality * **No pharmaceutical-grade supply exists:** MA-5 is not manufactured for human use anywhere. Trial material is supplied under the Japanese investigational program and is not available for purchase in any form or jurisdiction. * **Research-chemical vendors only:** The compound is catalogued by Selleck Chemicals, Cayman Chemical, MedChemExpress and MedKoo Biosciences under CAS 1354707-41-7, all explicitly labeled for research use only and not for human consumption. * **What to look for:** A batch-specific certificate of analysis, purity above 98% by high-performance liquid chromatography, identity confirmed by nuclear magnetic resonance and mass spectrometry, plus a residual-solvent statement. None of these substitutes for pharmaceutical manufacturing. * **Formulation considerations:** MA-5 is a poorly water-soluble carboxylic acid. Published work dissolves it in dimethyl sulfoxide, then dilutes in corn oil for oral dosing — a laboratory vehicle, not an oral dosage form fit for human use. * **Compounding pharmacies:** No compounding pharmacy holds a monograph or validated method for MA-5. A compounded preparation would rest on the same unqualified research-grade starting material, adding cost without adding assurance. * **Third-party testing:** No independent testing program covers MA-5. ConsumerLab, NSF and USP verification apply to marketed supplements, and none of them lists the compound, so no external check on vendor claims is available. ## Practical Considerations * **Time to effect:** Unknown in humans. In blinded mice, body weight separated from placebo around day 18 and kidney markers by day 27 ([Ogasawara et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42270754/)); worm motor benefits required exposure across adult life. Nothing shorter than several weeks has shown an effect. * **Common pitfall — treating cell-culture results as human doses:** Worm work used 10 µM in the medium and mice received 50 mg/kg ([Ogasawara et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42270754/)). Converting either to a human milligram figure without pharmacokinetic data produces an arbitrary number. * **Common pitfall — assuming a benign profile from press statements:** The claim of almost no side effects comes from an unpublished Phase I summary ([Science Japan report](https://sj.jst.go.jp/news/202601/n0119-01k.html)). Such a claim cannot be checked, and the only independent pharmacology found an off-target effect. * **Common pitfall — expecting benefit without a deficit:** Every measured effect required an existing mitochondrial deficit. Animals and cells with normal function showed little change, so a metabolically healthy person has the least to gain. * **Regulatory status:** Not approved in any jurisdiction. It is an investigational drug in Japan under an investigator-initiated trial, is not a dietary supplement ingredient in the United States or European Union, and cannot be sold for human use. * **Cost and accessibility:** Effectively inaccessible. Milligram quantities of research material cost roughly one to three hundred US dollars, and no route exists to a quantity, quality or formulation appropriate for human dosing. * **Payer incentives:** No health system pays for MA-5. If approved, it would compete against unpatented mitochondrial supplements costing a few dollars daily, giving insurers and national systems a structural incentive to favor the cheap incumbents in guideline and funding decisions. ## Interaction with Foundational Habits * **Sleep:** Direction unclear, mechanism plausible in both directions. Raising mitochondrial ATP output could support glymphatic clearance (the brain's overnight waste-flushing system), which is energy-intensive, while a compound acting on cellular energy state might disturb sleep onset. No study in any species has measured sleep architecture under MA-5, so neither expectation is supported. * **Nutrition:** Potentiating and blunting effects both plausible. MA-5's in-vitro inhibition of the carnitine shuttle predicts an interaction with high-fat and ketogenic patterns, which depend on that shuttle for fuel. A mixed diet with adequate carbohydrate would place least demand on the inhibited pathway. Published dosing used an oily vehicle, implying food improves absorption. * **Exercise:** Direction plausibly potentiating for endurance capacity but blunting during fasted training. Endurance exercise and MA-5 both increase mitochondrial capacity, though by different routes — biogenesis versus cristae remodelling — so effects need not add. Fasted or long-duration training relies on fatty-acid transport and is the setting where shuttle inhibition would surface first. * **Stress management:** Direction indirect, mechanism partly characterized. MA-5 reduces inflammatory signaling in brain immune cells through mitophagy — the recycling of damaged mitochondria ([Tan et al., 2021](https://pubmed.ncbi.nlm.nih.gov/33510088/)) — touching the neuroinflammatory arm of chronic stress rather than the cortisol axis. No study has measured cortisol or any stress biomarker under MA-5. ## Monitoring Protocol & Defining Success No monitoring protocol has been validated for MA-5, because no published human study exists. What follows is assembled from the biomarkers the animal and cell literature used to detect both its intended effect and its known off-target liability. Before any exposure, a baseline set establishes whether a mitochondrial deficit exists at all — since every measured benefit required one — and whether the fatty-acid transport pathway is already strained. That baseline should include a fasting metabolic panel with kidney and liver markers, a resting lactate, a carnitine panel, and formal audiometry given that hearing is the endpoint under trial. Ongoing monitoring, were exposure to occur, would repeat the carnitine panel and lactate at 4 weeks to catch shuttle inhibition early, repeat kidney and liver markers at 12 weeks, and thereafter re-measure the full set every 6 to 12 months alongside annual audiometry. | Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes | | --- | --- | --- | --- | | Resting lactate | 0.5–1.3 mmol/L | Primary readout of the mitochondrial deficit MA-5 targets | Fasting, seated 15 minutes, no tourniquet stasis; conventional labs accept up to 2.2 mmol/L, which is too permissive here | | GDF-15 | Below 750 pg/mL | The marker that fell with MA-5 in animals; tracks mitochondrial stress | GDF-15 stands for growth differentiation factor 15; also rises with kidney disease, smoking and age, so interpret against the individual's own baseline | | Free and total carnitine | Free 25–50 µmol/L; total 30–70 µmol/L | Detects inhibition of the carrier MA-5 blocks in vitro | Fasting sample; pair with the acylcarnitine profile drawn at the same draw | | Acylcarnitine-to-free-carnitine ratio | Below 0.25 | Rises early when fatty-acid entry into mitochondria is impeded | The most sensitive early signal of shuttle inhibition; best paired with lactate on the same sample | | Creatinine and eGFR | eGFR above 90 mL/min/1.73 m² | Kidney was the organ with the clearest animal response and the clearest injury signal | eGFR is the estimated glomerular filtration rate, a calculated measure of kidney filtering; conventional labs treat anything above 60 mL/min/1.73 m² as normal, which is far more permissive than the target here; avoid creatine supplementation for 2 weeks before | | BUN | 10–16 mg/dL | Second renal marker that moved with treatment in blinded mouse work | BUN is blood urea nitrogen; the conventional reference range of 7–20 mg/dL is wider at both ends than the target here; fasting, and confounded by high protein intake and dehydration | | ALT and AST | Both below 25 U/L | Liver is the presumed clearance route, and that route is unpublished | ALT and AST are liver enzymes released when liver cells are stressed; conventional upper limits of roughly 40–55 U/L sit far above the target here; fasting, and avoid within 48 hours of hard training | | Creatine kinase | 50–150 U/L | Muscle is a target tissue; detects muscle damage from any cause | Creatine kinase is a muscle enzyme released on muscle damage; conventional ranges extend to about 200 U/L, above the target here; avoid within 72 hours of resistance training | | Pure-tone audiometry | No established target — track change from the individual's own baseline in decibels at 4 and 8 kHz | Hearing is the endpoint the human trial was built around | Not a blood test; requires a sound-attenuated booth and the same equipment each time for comparability | Qualitative markers, tracked weekly against the pre-exposure baseline: * Exercise tolerance, especially in fasted or long-duration sessions, where shuttle inhibition would surface first * Time to fatigue during ordinary daily activity * Subjective clarity of hearing in noisy environments * Sleep quality and time to sleep onset * Cognitive clarity and sustained attention * Post-exertional recovery time ## Emerging Research * **The first human efficacy trial:** An investigator-initiated, double-blind, placebo-controlled Phase II study of oral MA-5 at low and high dose in patients with mitochondrial disease and hearing loss opened at four Japanese institutions in December 2025, registered as jRCT2031250505 ([Tohoku University announcement](https://www.tohoku.ac.jp/en/news/university_news/worlds_first_mitochondrial_disease_treatment_commences_clinical_trial.html)). * **No ClinicalTrials.gov registration exists:** Searches of ClinicalTrials.gov for MA-5 and for mitochonic acid return no study, so no NCT ID can be given. The trial is registered only in the Japanese registry, which limits independent access to its protocol and endpoints ([AMED announcement](https://www.amed.go.jp/en/news/release_20251119.html)). * **Independent off-target pharmacology could weaken the case:** The 2026 finding that MA-5 inhibits the carnitine/acylcarnitine carrier is the first characterization from outside the developing group, and predicts a fatty-acid oxidation liability that no in-vivo study has yet looked for ([Giangregorio et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42217682/)). * **Blinded replication is tightening the claims:** The first randomized, blinded, placebo-controlled rodent study confirmed renal benefit but found lactate lowering only under glucose loading and no cardiac histological benefit, narrowing effects that earlier unblinded work reported broadly ([Ogasawara et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42270754/)). * **Human stem-cell models are extending the disease range:** MA-5 improved muscle function in induced pluripotent stem cell models of Barth syndrome, a rare inherited cardiac and muscle disorder ([Tongu et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40542649/)). Stem-cell rescue remains in-vitro evidence, not a clinical endpoint. * **Acute neurological indications are opening:** MA-5 reduced neurological damage in a rodent ischemic stroke model ([Sasaibe et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40339682/)), extending the compound from chronic genetic disease toward acute injury and toward a different, faster-acting therapeutic logic. * **Human tissue outside the mitochondrial-disease frame:** MA-5 improved survival of human cartilage cells under oxidative stress via mitophagy pathways ([Xin et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35734404/)), suggesting relevance to age-related joint degeneration that no in-vivo study has yet tested. * **Pharmacokinetics remain the decisive gap:** No published study reports human absorption, half-life, tissue exposure or metabolism. Until those are public, no animal dose can be translated and no interaction with liver-cleared medicines can be predicted or excluded. ## Conclusion MA-5 is a laboratory-made molecule, built from a plant growth hormone, that gathers inside mitochondria and appears to raise the energy they produce by reshaping their internal folds rather than by driving the usual chemical reactions harder. Across cells taken from people with inherited energy disorders, across worms, and across mice, it has repeatedly raised energy output, lowered the damaging by-products of oxygen use, and protected kidney tissue, hearing and movement. Heart tissue responded in some studies and not in others. The breadth of these findings is striking. They are also, without exception, from cells and animals: no published study has measured a health outcome in a living person. The safety picture is correspondingly thin. An early safety study in healthy volunteers is described as uneventful, but its results have not been published, and one independent laboratory found that the compound blocks the transporter that carries fats into mitochondria — an effect never examined in a person. Most of the founding work comes from the group that invented the compound and stands to gain from its approval, and the program is funded by a national agency with its own stake in that outcome. This does not make the findings wrong, but it does concentrate much of the evidence base in a single interested source. For someone attentive to mitochondrial function and willing to act on early signals, MA-5 today is a promising laboratory compound with an unmeasured human profile and no route to material fit for use. **[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**